These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 15780823)

  • 1. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease.
    De Taeye B; Smith LH; Vaughan DE
    Curr Opin Pharmacol; 2005 Apr; 5(2):149-54. PubMed ID: 15780823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms].
    Banfi C; Mussoni L; Tremoli E
    Minerva Endocrinol; 2002 Sep; 27(3):181-91. PubMed ID: 12091793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.
    Takeshita Y; Takamura T; Hamaguchi E; Shimizu A; Ota T; Sakurai M; Kaneko S
    Metabolism; 2006 Nov; 55(11):1464-72. PubMed ID: 17046548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance.
    Alessi MC; Poggi M; Juhan-Vague I
    Curr Opin Lipidol; 2007 Jun; 18(3):240-5. PubMed ID: 17495595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy.
    Brazionis L; Rowley K; Jenkins A; Itsiopoulos C; O'Dea K
    Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):786-91. PubMed ID: 18239151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abdominal adiposity and cardiometabolic risk: do we have all the answers?
    Haffner SM
    Am J Med; 2007 Sep; 120(9 Suppl 1):S10-6; discussion S16-7. PubMed ID: 17720354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food deprivation induces adipose plasminogen activator inhibitor-1 (PAI-1) expression without accumulation of plasma PAI-1 in genetically obese and diabetic db/db mice.
    Oishi K; Ohkura N; Matsuda J; Ishida N
    Thromb Haemost; 2007 Oct; 98(4):864-70. PubMed ID: 17938813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of plasminogen activator inhibitor-1 and tissue plasminogen activator in the kidney of KKAy mice with type 2 diabetes].
    Chen LM; Li XW; Huang LW; Li Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):344-8. PubMed ID: 16038272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity.
    Juhan-Vague I; Alessi MC; Morange PE
    Ann Med; 2000 Dec; 32 Suppl 1():78-84. PubMed ID: 11209987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diabetes, coagulation and vascular events].
    Nenci GG; Paliani U
    Recenti Prog Med; 2000 Feb; 91(2):86-90. PubMed ID: 10748654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Plasminogen activator inhibitor-1 (PAI-1), ischemic heart disease and diabetes mellitus].
    Olexa P; Olexová M
    Vnitr Lek; 2003 Mar; 49(3):222-6. PubMed ID: 12728597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular complications in diabetes mellitus.
    Sobel BE; Schneider DJ
    Curr Opin Pharmacol; 2005 Apr; 5(2):143-8. PubMed ID: 15780822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.
    Festa A; Williams K; Tracy RP; Wagenknecht LE; Haffner SM
    Circulation; 2006 Apr; 113(14):1753-9. PubMed ID: 16585388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review).
    Jankun J; Al-Senaidy A; Skrzypczak-Jankun E
    Int J Mol Med; 2012 Jan; 29(1):3-11. PubMed ID: 21993838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAI-1 and the metabolic syndrome: links, causes, and consequences.
    Alessi MC; Juhan-Vague I
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2200-7. PubMed ID: 16931789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease.
    Nordt TK; Peter K; Ruef J; Kübler W; Bode C
    Thromb Haemost; 1999 Sep; 82 Suppl 1():14-8. PubMed ID: 10695479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A multicomparmental and multifactorial model of production of plasminogen activator inhibitor (PAI-1). I. Experimental studies].
    Galajda P; Kubisz P; Mokán M
    Vnitr Lek; 1998 Dec; 44(12):718-21. PubMed ID: 10422516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stroke prevention in diabetes and obesity.
    Kurukulasuriya LR; Govindarajan G; Sowers J
    Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):487-502. PubMed ID: 16918267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Plasminogen activator inhibitor (PAI-1) and diabetes mellitus. I. Regulation of PAI-1 levels].
    Galajda P; Sutarík L; Vladár L; Stasko J; Kubisz P; Mokán M
    Vnitr Lek; 1997 Dec; 43(12):804-8. PubMed ID: 9601894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.